Pancreatic neuroendocrine tumours

Best Practice and Research in Clinical Gastroenterology

Volumn 22, Issue 1, 2008, Pages 183-205

  Alexakis, N ^a   Neoptolemos, J P ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (United Kingdom)

Author keywords

chemotherapy; gastrinoma; insulinoma; multiple endocrine neoplasia 1; radionuclide therapy; surgery; Von Hippel Lindau

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; ALPHA INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; DACARBAZINE; DOXORUBICIN; ENDOSTATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; IRINOTECAN; OCTREOTIDE; PACLITAXEL; PENTETREOTIDE IN 111; PROTON PUMP INHIBITOR; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG;

ARTICLE; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GASTRINOMA; GLUCAGONOMA; HUMAN; INSULINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS RESECTION; PANCREAS SCINTISCANNING; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; VIPOMA; VON HIPPEL LINDAU DISEASE;

3-IODOBENZYLGUANIDINE; ANTINEOPLASTIC AGENTS; HORMONES; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED; VON HIPPEL-LINDAU DISEASE;

EID: 38349075905     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2007.10.008     Document Type: Article

References (125)

1. Alexakis N., Connor S., Ghaneh P., et al. Hereditary pancreatic endocrine tumours. Pancreatology 4 (2004) 417-435
2. Panzuto F., Nasoni S., Falconi M., et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12 (2006) 1083-1092
3. Plöckinger U., Rindi G., Arnold R., et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80 (2004) 394-424
4. Chu Q., Hill H., Douglass H., et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 9 (2002) 855-862
5. Vagefi P., Razo O., Deshpande V., et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms. Arch Surg 142 (2007) 347-354
6. Triponez F., Dosseh D., Goudet P., et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated non-functioning tumors of the pancreas. Ann Surg 243 (2006) 265-272
7. Lepage C., Rachet B., and Coleman M. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 132 (2007) 899-904
8. Fesinmeyer M., Austin M., Li C., et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1766-1773
9. Rindi G., Klöppel G., Alhman H., et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449 (2006) 395-401
10. Langer P., Kann P., Fendrich V., et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 28 (2004) 1317-1322
11. Rodallec M., Vilgrain V., Zins M., et al. Helical CT of pancreatic endocrine tumors. J Comput Assist Tomogr 26 (2002) 728-733
12. Debray M., Geoffroy O., Laissy J., et al. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 74 (2001) 1065-1070
13. Rodallec M., Vilgrain V., Couvelard A., et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6 (2006) 77-85
14. Dromain C., de Baere T., Lumbroso J., et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23 (2005) 70-78
15. Herwick S., Miller F., and Keppke A. MRI of islet cell tumors of the pancreas. AJR Am J Roentgenol 187 (2006) W472-W480
16. Gines A., Vazquez-Sequeiros E., Soria M., et al. Usefulness of EUS-guided fine needle aspiration (EUS-FNA) in the diagnosis of functioning neuroendocrine tumors. Gastrointest Endosc 56 (2002) 291-296
17. Gauger P., Scheiman J., Wamsteker E., et al. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 90 (2003) 748-754
18. Kann P., Balakina E., Ivan D., et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 13 (2006) 1195-1202
19. Nodit L., McGrath K., Zahid M., et al. Endoscopic ultrasound-guided fine needle aspirate microsatellite loss analysis and pancreatic endocrine tumor outcome. Clin Gastroenterol Hepatol 4 (2006) 1474-1478
20. Schillaci O., Spanu A., Scopinaro F., et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 44 (2003) 359-368
21. de Herder W., Hofland L., van der Lely A., et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 10 (2003) 451-458
22. Mirallie E., Pattou F., Malvaux P., et al. Value of endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Experience of 54 cases. Gastroenterol Clin Biol 26 (2002) 360-366
23. Bertherat J., Tenenbaum F., Perlemoine K., et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 88 (2003) 5353-5360
24. Ezziddin S., Logvinski T., Yong-Hing C., et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 47 (2006) 223-233
25. Quigley A., Buscombe J., Shah T., et al. Intertumoural variability in functional imaging within patients suffering from neuroendocrine tumours. An observational, cross-sectional study. Neuroendocrinology 82 (2005) 215-220
26. Meisetschlager G., Poethko T., Stahl A., et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 47 (2006) 566-573
27. Becherer A., Szabo M., Karanikas G., et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 45 (2004) 1161-1167
28. Orlefors H., Sundin A., Garske U., et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90 (2005) 3392-3400
29. Gotthardt M., Behe M., Grass J., et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 13 (2006) 1203-1211
30. Seemann M.D. Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18F-TOCA PET, triple-phase CT, and PET/CT. Technol Cancer Res Treat 6 3 (2007) 213-220
31. Doherty G., Olson J., Frisella M., et al. Lethality of multiple endocrine neoplasia type I. World J Surg 22 (1998) 581-587
32. Thomas-Marques L., Murat A., Delemer B., et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 101 (2006) 266-273
33. Lairmore T., Piersall L., DeBenedetti M., et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg 239 (2004) 637-645
34. Weber H., Venzon D., Lin J., et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108 (1995) 1637-1649
35. Teh S., Deveney C., and Sheppard B. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?. Am J Surg 193 (2007) 610-613
36. Matthews B., Smith T., Kercher K., et al. Surgical experience with functioning pancreatic neuroendocrine tumors. Am Surg 68 (2002) 660-665
37. Kazanjian K., Reber H., and Hines O. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (2006) 765-769
38. Sarmiento J., Farnell M., Que F., et al. Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. World J Surg 26 (2002) 1267-1271
39. Norton J., Kivlen M., Li M., et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138 (2003) 859-866
40. Fendrich V., Langer P., Celik I., et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244 (2006) 845-851
41. Bartsch D., Fendrich V., Langer P., et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242 (2005) 757-766
42. Van Nieuwenhove Y., Vandaele S., Op de Beeck B., et al. Neuroendocrine tumors of the pancreas. Surg Endosc 17 (2003) 1658-1662
43. Gupta S., Johnson M., Murthy R., et al. Hepatic arterial embolisation and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (2005) 1590-1602
44. Hochwald S., Zee S., Conlon K., et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (2002) 2633-2642
45. Hirshberg B., Libutti S., Alexander H., et al. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg 194 (2002) 761-764
46. Boukhman M., Karam J., Shaver J., et al. Insulinoma-experience from 1950 to 1995. West J Med 169 (1998) 98-104
47. Grama D., Skogseid B., Wilander E., et al. Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 16 (1992) 611-618
48. O'Riordain D., O'Brien T., van Heerden J., et al. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 18 (1994) 488-494
49. McAuley G., Delaney H., Colville J., et al. Multimodality preoperative imaging of pancreatic insulinomas. Clin Radiol 60 (2005) 1039-1050
50. Brandi M., Gagel R., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
51. Tisell L., Ahlman H., Jansson S., et al. Total pancreatectomy in the MEN-1 syndrome. Br J Surg 75 (1988) 154-157
52. Fernandez-Cruz L., Martinez I., Cesar-Borges G., et al. Laparoscopic surgery in patients with sporadic and multiple insulinomas associated with multiple endocrine neoplasia type 1. J Gastrointest Surg 9 (2005) 381-388
53. Thodiyil P., El-Masry N., and Williamson R. Achieving eugastrinaemia in Zollinger-Ellison syndrome: resection or enucleation?. Dig Surg 18 (2001) 118-123
54. Norton J., and Jensen R. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol 12 (2003) 145-151
55. Donow C., Pipeleers-Marichal M., Schroder S., et al. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 68 (1991) 1329-1334
56. Roy P., Venzon D., Shojamanesh H., et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 79 (2000) 379-411
57. Goudet P., Peschaud F., Mignon M., et al. Gastrinomas in multiple endocrine neoplasia type-1. A 127-case cohort study from the endocrine tumor group (ETG). Ann Chir 129 (2004) 149-155 [Article in French]
58. Bartsch D., Langer P., Wild A., et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?. Surgery 128 (2000) 958-966
59. Norton J., Fraker D., Alexander H., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 (1999) 635-644
60. Norton J., Alexander H., Fraker D., et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 234 (2001) 495-506
61. Pipeleers-Marichal M., Somers G., Willems G., et al. Gastrinomas in the duodenum of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 322 (1990) 723-727
62. MacFarlane M., Fraker D., Alexander H., et al. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 118 (1995) 973-979
63. Thompson N. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 243 (1998) 495-500
64. Lowney J., Frisella M., Lairmore T., et al. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 125 (1999) 1043-1049
65. Turner J., Wren A., Jackson J., et al. Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf) 57 (2002) 821-825
66. Imamura M., Komoto I., and Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg 30 (2006) 1-11
67. Doherty G. Multiple endocrine neoplasia type 1: duodenopancreatic tumors. Surg Oncol 12 (2003) 135-143
68. Akerstrom G., Hessman O., and Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck's Arch Surg 386 (2002) 558-569
69. Norton J., Fraker D., Alexander H., et al. Surgery increases survival in patients with gastrinoma. Ann Surg 244 (2006) 410-419
70. Farley D., van Heerden J., Grant C., et al. The Zollinger-Ellison syndrome. A collective surgical experience. Ann Surg 215 (1992) 561-569
71. Sheppard B., Norton J., Doppman J., et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 106 (1989) 1108-1118
72. Alexander H., Bartlett D., Venzon D., et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery 124 (1998) 1160-1166
73. Delcore R., and Friesen S. Role of pancreatoduodenectomy in the management of primary duodenal wall gastrinomas in patients with the Zollinger-Ellison syndrome. Surgery 112 (1992) 1016-1022
74. Cadiot G., Vuagnat A., Doukhan I., et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology 116 (1999) 286-293
75. Lairmore T., Chen V., DeBenedetti M., et al. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 231 (2000) 909-918
76. Stabile B., and Passaro E. Benign and malignant gastrinoma. Am J Surg 149 (1985) 144-149
77. Ruszniewski P., Podevin P., Cadiot G., et al. Clinical, anatomical and evolutive features of patients with the Zollinger-Ellison syndrome combined with type 1 multiple endocrine neoplasia. Pancreas 3 (1993) 295-304
78. Yu F., Venzon D., Serrano J., et al. Prospective study of the clinical course, prognostic factors, causes of death and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 17 (1999) 615-630
79. Gibril F., Venzon D., Ojeaburu J., et al. Prospective study of the natural history of gastrinoma in patients with MEN 1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86 (2001) 5282-5293
80. Gullo L., Migliori M., Falconi M., et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol 98 (2003) 2435-2439
81. Kang C., Kim K., Choi J., et al. Experiences with nonfunctioning neuroendocrine neoplasms of the pancreas. Dig Surg 22 (2005) 453-458
82. Solorzano C., Lee J., Pisters P., et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130 (2001) 1078-1085
83. Triponez F., Goudet P., Dosseh D., et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 30 (2006) 654-662
84. Levy-Bohbot N., Merle C., Goudet P., et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 28 (2004) 1075-1081
85. Soga J., and Yakuwa Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg 5 (1998) 312-319
86. House M., Cameron J., Lillemoe K., et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 10 (2006) 138-145
87. Strosberg J., Choi J., Cantor A., et al. Selective hepatic artery embolisation for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13 (2006) 72-78
88. Marrache F., Vullierme M., Roy C., et al. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 96 (2007) 49-55
89. Berber E., Flesher N., and Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26 8 (2002) 985-990
90. Mazzaglia P.J., Berber E., Milas M., et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142 1 (2007) 10-19
91. Olausson M., Friman S., Herlenius G., et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 13 (2007) 327-333
92. Mukhopadhyay B., Sahdev A., Monson J., et al. Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf) 57 (2002) 603-608
93. Libutti S., Choyke P., Bartlett D., et al. Pancreatic neuroendocrine tumours associated with Von Hippel-Lindau disease: Diagnostic and management recommendations. Surgery 124 (1998) 1153-1159
94. Libutti S., Choyke P., Alexander H., et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 128 (2000) 1022-1027
95. Yamasaki I., Nishimori I., Ashida S., et al. Clinical characteristics of pancreatic neuroendocrine tumors in Japanese patients with von Hippel-Lindau disease. Pancreas 33 (2006) 382-385
96. Delman K., Shapiro S., Jonasch E., et al. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg 30 (2006) 665-669
97. Wymenga A., Eriksson B., Salmela P., et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17 (1999) 1111-1117
98. Butturini G., Bettini R., Missiaglia E., et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 13 (2006) 1213-1221
99. Panzuto F., Di Fonzo M., Iannicelli E., et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17 (2006) 461-466
100. Hofland L., and Lamberts S. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24 (2003) 28-47
101. Ricci S., Antonuzzo A., Galli L., et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 23 (2000) 412-415
102. Faiss S., Pape U.F., Böhmig M., et al., International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 14 (2003) 2689-2696
103. Arnold R., Rinke A., Klose K., et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3 (2005) 761-771
104. Nguyen C., Faraggi M., Giraudet A.L., et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 10 (2004) 1660-1668
105. Frilling A., Weber F., Saner F., et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140 6 (2006) 968-976
106. Forrer F., Waldherr C., Maecke H.R., et al. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 26 1B (2006) 703-707
107. Valkema R., Pauwels S., Kvols L.K., et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36 2 (2006) 147-156
108. Kwekkeboom D., Teunissen J., Bakker W., et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23 (2005) 2754-2762
109. Fjallskog M.L., Granberg D.P., Welin S.L., et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 5 (2001) 1101-1107
110. Ramanathan R.K., Cnaan A., Hahn R.G., et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12 (2001) 1139-1143
111. Ansell S.M., Pitot H.C., Burch P.A., et al. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91 (2001) 1543-1548
112. Kulke M.H., Kim H., Clark J.W., et al. A phase II trial of gemcitabine for metastatic neuro-endocrine tumors. Cancer 101 (2004) 934-939
113. McCollum A., Kulke M., Ryan D., et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 27 (2004) 485-488
114. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (2004) 4762-4771
115. Bajetta E., Ferrari L., Procopio G., et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuro-endocrine tumours. Ann Oncol 13 (2002) 614-621
116. Delaunoit T., Ducreux M., Boige V., et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?. Eur J Cancer 40 (2004) 515-520
117. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 (2006) 401-406
118. Ekeblad S., Sundin A., Janson E., et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13 (2007) 2986-2991
119. Kulke M.H., Wu B., Ryan D.P., et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51 (2006) 1033-1038
120. Kulke M., Lenz H., Meropol N., et al. Results of a phase II study with sunitinib malate (SU11248) in patients with advanced neuroendocrine tumours ECCO. Eur J Cancer 3 (2005) 204
121. Kulke M.H., Stuart K., Earle C.C., et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 24 (2006) 4044
122. Kulke M.H., Bergsland E.K., Ryan D.P., et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24 22 (2006) 3555-3561
123. Hobday T., Holen K., Donehower R., et al. A phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: a phase II consortium study. J Clin Oncol 24 (2006) A4043 ASCO Annual Meeting Proceedings
124. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95 (2006) 1148-1154
125. Yao J., Phan T., Chang D., et al. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma. J Clin Oncol 24 (2006) A4042 ASCO Annual Meeting Proceedings